Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nerve Compression Syndromes

ClinicalTrials.gov lists 747 trials for Nerve Compression Syndromes or a narrower condition beneath it. University Hospital, Angers has the most among industry and government lead sponsors, with 7.

MeSH D009408 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 12 Phase 4 Phase 4 46 Not applicable Not applicable 467 Observational Observational 170 Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 12 Phase 4 Phase 4 46 Not applicable Not applicable 467 Observational Observational 170

Trials per phase (log scale)

31 of the 747 trials are tagged with Nerve Compression Syndromes itself; the rest are tagged with a narrower condition beneath it.

Get the Nerve Compression Syndromes report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nerve Compression Syndromes trials start? (27)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 88

1997: 1 trials (Not applicable 1) 1999: 1 trials (Phase 2 1) 2002: 3 trials (Observational 2, Not applicable 1) 2003: 5 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1) 2004: 3 trials (Not applicable 1, Phase 4 2) 2005: 3 trials (Not applicable 1, Phase 3 1, Phase 2/3 1) 2006: 7 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1/2 1) 2007: 8 trials (Observational 1, Not applicable 3, Phase 2 1, Phase 1/2 3) 2008: 7 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2009: 13 trials (Observational 2, Not applicable 7, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1) 2010: 13 trials (Observational 4, Not applicable 5, Phase 3 1, Phase 2 3) 2011: 12 trials (Observational 4, Not applicable 4, Phase 3 2, Phase 1 2) 2012: 13 trials (Observational 3, Not applicable 6, Phase 4 2, Phase 2 2) 2013: 21 trials (Observational 2, Not applicable 13, Phase 4 4, Phase 2 2) 2014: 20 trials (Observational 5, Not applicable 13, Phase 4 1, Phase 2 1) 2015: 19 trials (Observational 5, Not applicable 12, Phase 4 1, Phase 2/3 1) 2016: 33 trials (Observational 10, Not applicable 15, Phase 4 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2017: 16 trials (Observational 2, Not applicable 11, Phase 4 1, Phase 2 1, Phase 1 1) 2018: 39 trials (Observational 7, Not applicable 25, Phase 4 3, Phase 3 1, Phase 1 3) 2019: 39 trials (Observational 10, Not applicable 24, Phase 4 3, Phase 1/2 1, Phase 1 1) 2020: 42 trials (Observational 11, Not applicable 23, Phase 4 5, Phase 3 1, Phase 2/3 1, Phase 1/2 1) 2021: 52 trials (Observational 12, Not applicable 38, Phase 4 2) 2022: 79 trials (Observational 11, Not applicable 58, Phase 4 7, Phase 2 2, Phase 1 1) 2023: 88 trials (Observational 26, Not applicable 56, Phase 4 3, Phase 3 2, Phase 2/3 1) 2024: 66 trials (Observational 18, Not applicable 47, Phase 4 1) 2025: 73 trials (Observational 16, Not applicable 49, Phase 4 5, Phase 2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 69
2025 73
2024 66
2023 88
2022 79
2021 52
2020 42
2019 39
2018 39
2017 16

Forecast of the full-year count, planned starts included, not rows of this table: about 85 trials starting in 2026 and about 75 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 59 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 445 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nerve Compression Syndromes trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 13
Phase 1/2 8
Phase 2 25
Phase 2/3 6
Phase 3 12
Phase 4 46
Not applicable 467
Observational 170

How many Nerve Compression Syndromes trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 62
Recruiting 72
Enrolling by invitation 11
Active, not recruiting 18
Completed 417

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nerve Compression Syndromes trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
University Hospital, Angers 7

Which drugs are being tested for Nerve Compression Syndromes? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
METHYLPREDNISOLONE 8
Corticosteroid 6

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
[PRP] platelet rich plasma 11
L:Lidocaine 11
Exercise 8
Gabapentin 6% 7
Low Level Laser Therapy 6

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nerve Compression Syndromes trials report? (5)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 3 1
Arthritis 2 1
Fracture 1 1
Myocardial infarction 1 1
Nerve Injury - Digital-Median 1 1

Which publications cover Nerve Compression Syndromes? (219)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages